Alzther Industries a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s Disease and companion diagnostics for the early detection of Alzheimer’s Disease, today announced that Sung Eung-Yung Ph.D., has been chosen as recipient of the Alzheimer Award presented by the Compendium Medicinalis in recognition of his outstanding work, “A Pioneering Technique Test for the Early Detection of Alzheimer’s disease”.
“My co-authors and I are extremely pleased to have been chosen by a distinguished group of peers as the recipients of this year’s Compendium Medicinalis of Alzheimer’s Disease award for our work on the development of the 96-gene expression test for detection of early Alzheimer’s disease,” said Dr. Eung-Yung, Research Director for Alzther Industries.
Each year the Associate Editors of the Alzheimer’s disease Compendium Medicinalis vote to select an outstanding article from the previous year's volumes to receive this prestigious award. Dr. Eung-Yung will be presented with the bronze Alzheimer Medal with the likeness of Alois Alzheimer.
Dr. Eung-Yung and the team investigated the diagnostic value of a 96-gene expression test for detection of early AD. A disease classification algorithm was developed and was validated in two steps using two independent test sets. A similar accuracy, sensitivity and specificity were achieved both in the initial analysis and in the two independent test sets. When compared with available biomarker data high agreement was found.
Dr. Eung-Yung goes on to suggest that the gene expression test using a convenient blood sample can aid the diagnosis of mild to moderate AD.

[b]About Alzther Industries[/b]
Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

www.alzther.com